Distant bell starts to toll for near-bankrupt Clovis

10 November 2022
drug_money_man_stock_large

The game is nearly up for Clovis Oncology (Nasdaq: CLVS).

Founded in 2009, the Colorado, USA-based biotech has focused on developing and commercializing cancer products but its fortunes have been dependent on the success of the company’s wholly-owned PARP inhibitor, Rubraca (rucaparib).

"We will not have sufficient liquidity to maintain our operations beyond January 2023"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology